---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-093920"
form_type: "8-K"
ticker: "EVMN"
cik: "0002044725"
company_name: "Evommune, Inc."
filed_at: "2026-03-05T23:59:59+00:00"
generated_at: "2026-05-15T20:01:44.341012+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Evommune reports Q4/FY2025 net loss $28.3M/$68.9M; positive EVO301 Ph2a data; $125M raise

## Summary
- Q4 net loss $28.3M; FY net loss $68.9M vs $66.8M prior year. Revenue $13.0M FY (Maruho deal). Cash $216.7M at Dec 31, 2025.
- Positive Phase 2a POC data for EVO301 in atopic dermatitis: met primary endpoint, 33% placebo-adjusted EASI reduction at week 12 after 2 doses.
- EVO756 Phase 2b top-line data expected 2Q26 for CSU, 2H26 for AD; Phase 2b in migraine to start mid-2026.
- Closed $125M private placement in Feb 2026; cash runway extended through 2028.

## SEC filing metadata
- accession: 0001193125-26-093920
- form_type: 8-K
- ticker: EVMN
- cik: 0002044725
- company_name: Evommune, Inc.
- filed_at: 2026-03-05T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2044725/000119312526093920/0001193125-26-093920-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2044725/000119312526093920/evmn-20260305.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-093920
- JSON: https://secwatch.observer/filing/0001193125-26-093920.json
- Plain text: https://secwatch.observer/filing/0001193125-26-093920.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.